AndreaBozzo/ceres-open-data-index huggingface dataset:
A Review of the Adverse Effects of Peripheral Alpha-1 Antagonists in Hypertension Therapy

Background
          Doxazosin and its role as an antihypertensive agent have come under recent scrutiny as a result of the early termination of that treatment arm in ALLHAT. It is unclear why the cardiovascular (CV) event rate in this randomized, controlled trial (RCT), especially heart failure, is higher in those treated with a doxazosin-based regimen than with a chlorthalidone based-regimen. There has been little work in the past to summarize information on peripheral alpha-1 antagonists that may be helpful in evaluating the results of this randomized controlled trial.
        
        
          Methods
          Using Medline and the Cochrane databases, we performed a comprehensive review of the literature on the use of peripheral alpha-1 antagonists as antihypertensive agents, focusing on available information that could explain the excess cardiovascular events observed in the Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT).
        
        
          Results
          Minimal data were available concerning the effects of peripheral alpha-1 antagonists on CV endpoints. A multitude of short-term studies-ranging from small observational studies to short-term moderate-sized RCTs – focused on safety, efficacy, and tolerability, and some studies investigated the physiologic effects of these agents. These previously reported studies reveal associations with weight gain, fluid retention, and neurohormonal changes among various populations of those treated with peripheral alpha-1 antagonists.
        
        
          Conclusion
          These findings suggest several possible mechanisms by which doxazosin may be inferior to low-dose diuretics as antihypertensive therapy for the prevention of heart failure.
2016  Uniform Reporting System (URS) Table for Federated States of Micronesia

This is the 2016 Uniform Reporting System (URS) Output Tables for Federated States of Micronesia. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Timolol maleate

Timolol Maleate is a prescription eye drop medication that lowers pressure inside the eye to treat glaucoma or ocular hypertension. Available in 0.25% and 0.5% strengths, it's a beta-blocker applied directly to the eyes. Manufactured by Ingenus Pharmaceuticals, LLC, under NDC 50742-288, it comes in 0.3 mL containers. This information was generated using AI and is provided for informational and research purposes only.
Insights into rheumatoid arthritis derived from the Sa immune system

The Sa system is a recently described immune system that has a specificity and positive predictive value of nearly 100% for rheumatoid arthritis (RA) in Asia, Europe and the Americas. Its sensitivity of 30-40% suggests that it identifies a subset of RA patients. Anti-Sa antibodies are present from disease onset and are predictive of disease severity. The immune reactants are plentiful in the target tissue: antigen is present in the synovium, IgG antibody in the fluid. Immunologically, Sa is a hapten-carrier antigen in which vimentin is the carrier and citrulline is the hapten. The citrullination of vimentin is closely related to apoptosis, and citrullinated vimentin is extremely sensitive to digestion by the ubiquitous calpains. Nevertheless, Sa is found in only a few cell lines. Calpastatin, the natural specific inhibitor of calpains, is also a RA-associated, albeit non-specific, autoimmune system. Is it possible that calpain-related apoptotic pathways could be prominent in cells containing Sa? The task is to reconcile the specificity of Sa/citrullinated proteins in a multifactorial and polygenic disease such as RA.
Impaired Driving Death Rate, by Age and Sex, 2012 & 2014, Region 5 - Chicago

Rate of deaths by age/gender (per 100,000 population) for people killed in crashes involving a driver with BAC =>0.08%, 2012, 2014. 2012 Source: Fatality Analysis Reporting System (FARS). 2014 Source: National Highway Traffic Administration's (NHTSA) Fatality Analysis Reporting System (FARS), 2014 Annual Report File. Note: Blank cells indicate data are suppressed. Fatality rates based on fewer than 20 deaths are suppressed.
Compound 528573: tert-Butyl(dimethyl)silyl laurate

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] dodecanoate. Molecular Formula: C18H38O2Si. Molecular Weight: 314.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528165: 1,3-Cyclopentadiene, 1-decyl

Chemical compound data from PubChem database. IUPAC Name: 1-decylcyclopenta-1,3-diene. Molecular Formula: C15H26. Molecular Weight: 206.37. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Dynamic compression nail: A preliminary report

Background
          Interlocking nailing, which has become the method of choice for treating fractures of the femoral and tibial shafts, still lacks ability to provide the important contact-compression at the fracture. An intramedullary compression nail is described, which provides axial compression at the fracture site with tightening of the specially designed distal interlocking screw. This uses the same principle as dynamic compression plating.
        
        
          Methods
          The study included 11 femoral and tibial nailings performed for various clinical applications such as acute fractures, non-unions and malunions.
        
        
          Results
          All the fractures attained radiological union, with good skeletal continuity across the fracture, within an average time of 13 weeks in fresh fractures and 18 weeks in non-unions.
        
        
          Conclusions
          Active compression through intramedullary compression nailing has great utility for treating non-unions where it provides greater degree of impaction of its irregular ends. This may prove greatly advantageous to the fracture union through increased stability and the osteogenic potential, particularly when utilized in combination with the small diameter unreamed nails.
Analysis of human sarcospan as a candidate gene for CFEOM1

Background
          Congenital fibrosis of the extraocular muscles type 1 (CFEOM1) is an autosomal dominant eye movement disorder linked to the pericentromere of chromosome 12 (12p11.2 - q12). Sarcospan is a member of the dystrophin associated protein complex in skeletal and extraocular muscle and maps to human chromosome 12p11.2. Mutations in the genes encoding each of the other components of the skeletal muscle sarcospan-sarcoglycan complex (α - δ sarcoglycan) have been shown to cause limb girdle muscular dystrophy (LGMD2C-F). To determine whether mutations in the sarcospan gene are responsible for CFEOM1 we: (1) attempted to map sarcospan to the CFEOM1 critical region; (2) developed a genomic primer set to directly sequence the sarcospan gene in CFEOM1 patients; and (3) generated an anti-sarcospan antibody to examine extraocular muscle biopsies from CFEOM1 patients.
        
        
          Results
          When tested by polymerase chain reaction, sarcospan sequence was not detected on yeast or bacterial artificial chromosomes from the CFEOM1 critical region. Sequencing of the sarcospan gene in CFEOM1 patients from 6 families revealed no mutations. Immunohistochemical studies of CFEOM1 extraocular muscles showed normal levels of sarcospan at the membrane. Finally, sarcospan was electronically mapped to bacterial artificial chromosomes that are considered to be outside of the CFEOM1 critical region.
        
        
          Conclusions
          In this report we evaluate sarcospan as a candidate gene for CFEOM1. We have found that it is highly unlikely that sarcospan is involved in the pathogenesis of this disease. As of yet no sarcospan gene mutations have been found to cause muscular abnormalities.
A new device for measurement of fibrin clot lysis: application to the Euglobulin Clot Lysis Time

Background
          Determination of clot lysis times on whole blood, diluted whole blood, plasma or plasma fraction has been used for many years to assess the overall activity of the fibrinolytic system. We designed a completely computerised semi-automatic 8-channel device for measurement and determination of fibrin clot lysis. The lysis time is evaluated by a mathematical analysis of the lysis curve and the results are expressed in minute (range: 5 to 9999). We have used this new device for Euglobulin Clot Lysis Time (ECLT) determination, which is the most common test used in laboratories to estimate plasma fibrinolytic capacity.
        
        
          Results
          The correlation between ECLT and manual method is very tight : R = 0,99; p < 10-6. The efficiency scores of the method are <4% in intra-assay and <7% in inter-assay. It allows to achieve the tests on hyperlipaemic samples. This new device has been easily integrated in laboratory routine and allows to achieve several ECLT every day without disturbance of laboratory workflow.
        
        
          Conclusions
          The routine use of this new device could be useful in various situations such as assessment in atherosclerosis and arteriosclerosis associated diseases, coagulation survey of liver transplantations, cardiovascular surgery or pharmacological research.
          It has already provided highly promising results in preliminary studies on the relation between fibrinolysis and cardiovascular risk factors.
4.15b Facility licensing, certification, or accreditation, by facility operation and primary focus of facility: 2011. Percent

This is a National Survey of Substance Abuse Treatment Services (N-SSATS) data table showing facility licensing, certification, or accreditation, by facility operation and primary focus of facility in 2011. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.
Program Instruction (PI-05-05)

This Program Instruction (PI) provides instruction to Tribes on the June 30, 2005 submission of the Annual Progress and Services Report (APSR) required under Title IV-B of the Social Security Act (the Act), and the CFS-101, Parts I and II, Annual Budget Request and Annual Summary of Child and Family Services.

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E399816-T1: [Translated] REACTIVE FLAME RETARDANTS AND FLAME RETARDANT RESIN PRODUCTS

The invention provides a reactive flame retardant which can impart excellent flame retardance to a resin when added to the resin even in a small amount and are freed from bleed out; and a product made of flame-retarded resin obtained by using the same. According to the invention, an organic cyclic phosphorus compound represented by the general formula (I) which has at least one unsaturated group at the end of R 1  is used as the reactive flame retardant. The product made of flame-retarded resin can be obtained by solidifying a resin composition containing the organic cyclic phosphorus compound and then reacting the composition by heating or irradiation with a radiation.
Assessing the quality of reports of systematic reviews in pediatric complementary and alternative medicine

Objective
          To examine the quality of reports of complementary and alternative medicine (CAM) systematic reviews in the pediatric population. We also examined whether there were differences in the quality of reports of a subset of CAM reviews compared to reviews using conventional interventions.
        
        
          Methods
          We assessed the quality of reports of 47 CAM systematic reviews and 19 reviews evaluating a conventional intervention. The quality of each report was assessed using a validated 10-point scale.
        
        
          Results
          Authors were particularly good at reporting: eligibility criteria for including primary studies, combining the primary studies for quantitative analysis appropriately, and basing their conclusions on the data included in the review. Reviewers were weak in reporting: how they avoided bias in the selection of primary studies, and how they evaluated the validity of the primary studies. Overall the reports achieved 43% (median = 3) of their maximum possible total score. The overall quality of reporting was similar for CAM reviews and conventional therapy ones.
        
        
          Conclusions
          Evidence based health care continues to make important contributions to the well being of children. To ensure the pediatric community can maximize the potential use of these interventions, it is important to ensure that systematic reviews are conducted and reported at the highest possible quality. Such reviews will be of benefit to a broad spectrum of interested stakeholders.
Patent AT-E40182-T1: [Translated] COMBINED GAS/STEAM TURBINE PROCESS.

1. Process for carrying out a combined gas turbine/steam turbine process in which the gas turbine process is carried out by means of a fuel gas which has been obtained from solid carbonaceous material and subsequently de-sulphurated, and the steam turbine process is carried out by means of the steam obtained upon combustion of the carbonaceous gasification residue, and in which the combustion of the carbonaceous gasification residue takes place with oxygen-containing waste gases from the gas turbine process, characterised in that the fuel gas is produced in a circulating fluidised bed by gasification of 70 to 95% weight of the carbon content in the carbonaceous material at a temperature of 900 to 1,100 degrees C, is freed of pollutants at 850 to 950 degrees C in the suspended state with calcium hydroxide, calcium oxide and/or calcium carbonate-containing solid, and is burned for the predominant part for the operation of the gas turbine to produce a gas containing at least 5% vol. oxygen and being at 1,000 degrees C at least, the combustion of the carbonaceous gasification residue being carried out under near-stoichiometric conditions with the production of process steam in another circulating fluidised bed at a temperature of 800 to 950 degrees C with oxygen-containing gases which are supplied in at least two sub-streams at different levels, which are predominantly formed from the gas turbine waste gas.
Child Welfare Outcomes 2017: Report to Congress

This report to Congress provides information on the performance of states on seven national outcome categories and also includes data on contextual factors and findings of analyses conducted across states.

(PDF  (PDF)- 4,518KB)

(PDF (PDF) - 945KB)

The PDF is best viewed in Chrome or Firefox. If using Internet Explorer (IE), please right click the link, save the file, and view it locally.

Executive Summary

Contextual Factors

State Performance on Outcome Measures

Conclusion and Recommendations for Further Investigation

Child Welfare Outcomes Data Site

Introduction to the Child Welfare Outcomes, Data, and Analysis

Outcome Measures

Context Data

Data Sources

Data Analyses in the Report

The Child Welfare Outcomes Report Data Site

Chapter 1: Child Welfare Outcomes Demographic Data

National Child Population

Children in Foster Care

Foster Care Entry Rates

Children Waiting for Adoption and Children Adopted

Summary

Chapter 2: Keeping Children Safe

Child Victims and Child Fatalities

Range of State Performance on Safety-Related Outcome Measures

Changes Over Time in State Performance on Measures of Maltreatment Recurrence and Maltreatment of Children in Foster Care

Summary of Findings Regarding Keeping Children Safe

Chapter 3: Finding Permanent Homes for Children in Foster Care

Range of Performance in Achieving Permanency for Children in Foster Care

Changes Over Time in State Performance on Measures of Achieving Permanency

Summary of Findings Regarding Achieving Permanency for Children in Foster Care

Chapter 4: Achieving Timely Reunifications and Adoptions for Children in Foster Care

Caseworker Visits

Timeliness of Reunifications

Changes Over Time in State Performance With Regard to Achieving Timely Reunifications

Timeliness of Adoptions

Changes Over Time in State Performance With Regard to Timeliness of Adoptions

Summary of Findings Regarding Achieving Reunifications and Adoptions in a Timely Manner

Chapter 5: Achieving Stable and Appropriate Placement Settings for Children in Foster Care

Changes Over Time in State Performance on Measures of Achieving Stable and Appropriate Placement Settings for Children in Foster Care

Summary of Findings Regarding Achieving Stable and Appropriate Placements for Children in Foster Care

Chapter 6: State Comments on Performance Relevant to the Seven National Child Welfare Outcomes

Appendix A: Adoption and Safe Families Act of 1997 (Pub. L. 105—89)

Appendix B: Child Welfare Outcomes Report: Outcomes and Measures

Appendix C: Caseworker Visits

Appendix D: Child Welfare Outcomes Report: Data Sources and Elements

Appendix E: Child Maltreatment 2017: Summary of Key Findings

Appendix F: The AFCARS Report: FY 2017 Estimates

Appendix G: Data-Quality Criteria

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E401008-T1: [Translated] METHOD FOR DISPERSING VEGETABLE STEROL IN BEVERAGES AND A DRINK WITH DISPERSED VEGETABLE STEROL WITH A PARTICLE SIZE IN THE NANOMETER RANGE

Disclosed are a method for dispersing plant sterol for beverage and a plant sterol-dispersed beverage, of which particle size is nanometer-scale in dispersed beverage. The dispersion of plant sterols starts with the admixing of plant sterol to at least one emulsifier selected from the group consisting of sucrose fatty acid ester, sorbitan fatty acid ester and polyglycerine fatty acid ester, followed by melting the admixture by heating at 60 to 200° C. Afterwards, the molten substance is mixed with an aqueous beverage alone or an emulsifier-containing aqueous beverage in state of its own molten type or power type. This resulting mixture is stirred at a high speed to give a dispersion of plant sterols in an aqueous beverage. The beverage is superior in bioavailability, having good mouth feel, transparent aspect and no influence on the characteristic taste, flavor and color of the beverages.
Compound 529233: Pentanoic acid, 2-amino, O,N,N-tris-TMS

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-[bis(trimethylsilyl)amino]pentanoate. Molecular Formula: C14H35NO2Si3. Molecular Weight: 333.69. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399577-T1: [Translated] FLUID DRAIN DEVICE FOR TREATING HYDROCEPHALUS

A cerebrospinal fluid shunt system comprises a brain ventricle catheter ( 15 ) to insert into the brain ventricle ( 21 ) so as to drain cerebrospinal fluid from the brain ventricle, a sinus catheter ( 18 ) to insert into the sinus sagittalis system ( 22 ) for feeding the cerebrospinal fluid into the sinus sagittalis system, a shunt body member ( 10 ) connected at one end thereof to said brain ventricle catheter and at another end thereof to said sinus catheter system to provide fluidic communication between said brain ventricle catheter ( 15 ) and said sinus catheter ( 18 ), and a flow restriction ( 16 ) defined within the shunt body member ( 10 ) to maintain a resistance to fluid flow of the shunt system of less than 8 mm Hg/ml/min, such as 2-7 or 4-6 and preferably about 5 mm Hg/ml/min. When the shunt system is implanted the shunt body member ( 10 ) is placed subcutaneously on top of the calvarium of a patient, behind the coronal suture on one of side of the sagittal suture. One end of each of the catheters ( 15, 18 ) is then connected to a respective end of the shunt body member ( 10 ), and a second end of each catheter is inserted in the right ventricle ( 21 ) and in the sinus sagittalis system ( 22 ), respectively, via holes bored in the scull ( 19 ).
Compound 530441: 4-Ethylbenzoic acid, dodec-9-ynyl ester

Chemical compound data from PubChem database. IUPAC Name: dodec-9-ynyl 4-ethylbenzoate. Molecular Formula: C21H30O2. Molecular Weight: 314.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Victimization and Other Risk Factors for Child Maltreatment Among School-Age Parents: A Longitudinal Study, 1988- 1992

This descriptive longitudinal field study looks at risk factors in the etiology of child abuse and neglect among adolescent parents. The investigators examined sexual victimization prior to pregnancy as a major antecedent factor for child maltreatment. Pregnant and/or parenting adolescents were recruited from ongoing educational and social programs in the state of Washington between October 1988 and 1989. The sample consisted of 535 adolescent females who were 17 years old or younger at the time of their first pregnancy, and 21 years old or younger at the time they completed the survey. Follow-up data for this study were collected on 315 of these females between 1990 and 1991. The survey data describe respondents demographic characteristics, family background, pregnancies, parenting history, sexual histories, behavioral indicators of sexual victimization, physical maltreatment, and neglect. In addition, data were collected on parenting skills, attitudes, social support, sex roles and attitudes toward sexual activity. The data allow for examination of the inter-relationship between:  1) childhood sexual abuse, 2) adolescent pregnancy, and 3) child maltreatment by adolescent parents. The Archive distributes two data files for this study.  One file contains the baseline data collected between 1988 and 1989 for all 540 participants in wave one.  The second data file includes baseline and follow-up data for the 318 women who participated in both waves of the study.

Investigators: Boyer, D., & Fine, D.
Compound 526656: (1-(4-Chlorophenyl)propan-2-yl)(ethyl)amine

Chemical compound data from PubChem database. IUPAC Name: 1-(4-chlorophenyl)-N-ethylpropan-2-amine. Molecular Formula: C11H16ClN. Molecular Weight: 197.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2010 CMHS Uniform Reporting System (URS) Output Tables for Minnesota

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2010. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.